Inferensys

Glossary

ADMET Prediction

The in silico forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties, used early in drug discovery to filter out molecules with poor pharmacokinetic or safety profiles.
Strategy consultant facilitating AI use case discovery workshop, sticky notes on glass wall, casual corporate meeting.
PHARMACOKINETIC FORECASTING

What is ADMET Prediction?

The in silico forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties, used early in drug discovery to filter out molecules with poor pharmacokinetic or safety profiles.

ADMET prediction is the computational process of forecasting a molecule's pharmacokinetic and toxicity profile—its Absorption, Distribution, Metabolism, Excretion, and Toxicity—before synthesis. By applying machine learning models trained on experimental data, these predictions identify compounds likely to fail due to poor bioavailability, rapid clearance, or off-target toxicity, enabling early-stage attrition of unsuitable candidates.

Modern ADMET models leverage graph neural networks and molecular fingerprints to learn structure-property relationships from curated databases. Key endpoints include Caco-2 permeability, cytochrome P450 inhibition, hERG cardiotoxicity, and plasma protein binding. Integrating these predictions into multi-parameter optimization workflows allows medicinal chemists to balance potency with drug-like properties, reducing costly late-stage clinical failures.

PHARMACOKINETIC PROFILING

Core ADMET Endpoints

The in silico forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties, used early in drug discovery to filter out molecules with poor pharmacokinetic or safety profiles.

01

Absorption & Permeability

Predicts a compound's ability to cross biological membranes, primarily the intestinal wall, to reach systemic circulation. Key models forecast Caco-2 permeability and PAMPA values. Lipinski's Rule of Five serves as a foundational filter, flagging molecules with poor absorption due to high molecular weight (>500 Da), excessive hydrogen bond donors (>5), or high logP (>5). Modern graph neural networks directly predict the fraction absorbed in humans from molecular structure.

02

Distribution & Volume

Models the reversible transfer of a drug from the bloodstream into tissues and organs. Critical predictions include volume of distribution (Vd) and plasma protein binding (PPB) . A high Vd indicates extensive tissue binding, while high PPB limits the free, pharmacologically active fraction. AI models trained on human pharmacokinetic data can now predict blood-brain barrier penetration, a crucial parameter for CNS-targeted therapeutics.

03

Metabolism & Clearance

Forecasts the enzymatic biotransformation of a compound, primarily by the cytochrome P450 (CYP) enzyme family in the liver. Models predict intrinsic clearance (CLint) and identify specific sites of metabolism (SOM) . A key liability is CYP3A4 inhibition, which can cause dangerous drug-drug interactions. Deep learning models classify compounds as substrates or inhibitors of major CYP isoforms to predict metabolic stability.

04

Excretion & Half-Life

Predicts the removal of a compound and its metabolites from the body, primarily via renal or biliary routes. This is tightly coupled with metabolism to determine half-life (t1/2) , the time required for plasma concentration to drop by 50%. A short half-life necessitates frequent dosing, while an excessively long half-life risks accumulation. Models integrate clearance and volume of distribution data to forecast this critical dosing interval parameter.

05

Toxicity & Safety Liabilities

The most critical endpoint, forecasting adverse effects. In silico models flag structural alerts for mutagenicity (Ames test) , cardiotoxicity (hERG channel block) , and hepatotoxicity (DILI) . Advanced deep learning models trained on toxicogenomics data can predict complex organ-level toxicities. Identifying Pan-Assay Interference Compounds (PAINS) is also crucial to avoid false leads that appear active due to non-specific reactivity.

06

Multi-Parameter Optimization (MPO)

The simultaneous balancing of all ADMET properties to find a compound with an optimal overall profile. A potent molecule with poor solubility or high toxicity is a dead end. MPO algorithms use desirability functions to score compounds against a target product profile, trading off conflicting properties. This computational triage ensures only high-quality, drug-like candidates advance to costly in vivo studies.

ADMET PREDICTION FAQ

Frequently Asked Questions

Clear, technically precise answers to the most common questions about in silico ADMET prediction, covering mechanisms, model types, data requirements, and practical application in drug discovery workflows.

ADMET prediction is the computational forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties using machine learning and physics-based models. It works by training quantitative structure-property relationship (QSPR) models on curated experimental datasets, where molecular descriptors—ranging from simple physicochemical properties like logP and molecular weight to complex graph neural network embeddings—are mapped to pharmacokinetic endpoints. During inference, a novel molecule's structure is featurized and passed through the trained model to output a predicted value (e.g., Caco-2 permeability in cm/s) or a classification (e.g., hERG blocker/non-blocker). Modern implementations often use multitask deep neural networks that learn shared representations across multiple ADMET assays simultaneously, improving generalization through inductive transfer. The goal is to fail early and cheaply: filtering out molecules with poor pharmacokinetic or safety profiles before costly synthesis and in vivo testing.

Prasad Kumkar

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.